Allergic diseases are on the rise in many parts of the world. Second-generation antihistamines are the first-line treatment option. International guidelines describe the management of these conditions; however, clinicians perceive the additional need to tailor treatment according to patient profiles. This study serves as a consensus of experts from several countries in APAC. This study aims to describe the unmet needs, practical considerations, challenges, and key decision factors when determining optimal second-generation antihistamines for patients with allergic rhinitis and/or urticaria.
Specialists from allergology, dermatology, and otorhinolaryngology were surveyed on practical considerations. Key decision points were also asked when treating patients with allergic rhinitis and/or urticaria.
Clinicians felt the need for additional tools for diagnosis of these diseases and a single drug with all preferred features of an antihistamine. The selection of optimal second-generation antihistamines depends on many factors, particularly drug safety and efficacy, impact on psychomotor abilities, and sedation. The results reveal bilastine as a preferred choice due to its high efficacy and safety, suitability for special patient populations, and the lack of sedative effects.
The study concluded through the findings that compliance with the international guidelines is present among allergists, dermatologists, and otorhinolaryngologists; however, this is lower amongst GPs.